Cargando…

AZP2006, a new promising treatment for Alzheimer’s and related diseases

Progranulin (PGRN) is a protein with multiple functions including the regulation of neuroinflammation, neuronal survival, neurite and synapsis growth. Although the mechanisms of action of PGRN are currently unknown, its potential therapeutic application in treating neurodegenerative diseases is huge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Callizot, N., Estrella, C., Burlet, S., Henriques, A., Brantis, C., Barrier, M., Campanari, M. L., Verwaerde, P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376949/ https://www.ncbi.nlm.nih.gov/pubmed/34413330 http://dx.doi.org/10.1038/s41598-021-94708-1

Ejemplares similares

Huperzia serrata Extract ‘NSP01’ With Neuroprotective Effects-Potential Synergies of Huperzine A and Polyphenols
por: Callizot, N., et al.
Publicado: (2021)

Three-dimensional growth of breast cancer cells potentiates the anti-tumor effects of unacylated ghrelin and AZP-531
por: Au, CheukMan C, et al.
Publicado: (2020)

MON-102 Nonclinical Development of AZP-531 (Livoletide): A Peptide Analog of Unacylated Ghrelin for the Treatment of Hyperphagia in Prader-Willi Syndrome
por: Milano, Stephane, et al.
Publicado: (2019)

AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial
por: Allas, Soraya, et al.
Publicado: (2018)

OR23-04 Treatment Of Chronic Hypoparathyroidism With Eneboparatide (AZP-3601), A Novel PTH 1 Receptor Agonist: Results From A Phase 2 Trial
por: Kamenicky, Peter, et al.
Publicado: (2023)

ODP353 Sustained Suppression of IGF1 with AZP-3813, a Bicyclic 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor and a Potential New Treatment for Acromegaly
por: Culler, Michael, et al.
Publicado: (2022)

SUN-609 Livoletide (AZP-531), an Unacylated Ghrelin Analogue, Improves Hyperphagia and Food-Related Behaviors Both in Obese and Non-Obese People with Prader-Willi Syndrome
por: Harisseh, Rania, et al.
Publicado: (2020)

AZP-3404, a Peptide Analog of IGFBP-2, Induces Weight Loss and Improves Glucose Metabolism in Leptin-Resistant db/db Mice
por: Culler, Michael D, et al.
Publicado: (2021)

Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy
por: Chumakov, Ilya, et al.
Publicado: (2015)

SAT237 AZP-3601, A Novel PTH 1 Receptor Agonist, Induces Rapid Reduction And Normalization Of Urinary Calcium In Chronic Hypoparathyroid Patients
por: Figueres, Lucile, et al.
Publicado: (2023)

THU046 Repeated Treatment With AZP-3813, A Bicyclic, 16-Amino Acid Peptide Antagonist Of The Human Growth Hormone Receptor, Induces Enhanced Suppression Of IGF1 In Beagle Dogs
por: Ravel, Guillaume, et al.
Publicado: (2023)

Necrosis, apoptosis, necroptosis, three modes of action of dopaminergic neuron neurotoxins
por: Callizot, Noëlle, et al.
Publicado: (2019)

Treatment of Talipes Equino-Varus
por: Barrier, C. W.
Publicado: (1893)

OR21-6 AZP-3601, a Long-Acting Parathyroid Hormone (PTH) Analog, Normalizes Blood Calcium in Thyroparathyroidectomized (TPTX) Rats Without Causing Deleterious Changes in Bone
por: Culler, Michael, et al.
Publicado: (2022)

Ceramide and Related-Sphingolipid Levels Are Not Altered in Disease-Associated Brain Regions of APP(SL) and APP(SL)/PS1(M146L) Mouse Models of Alzheimer's Disease: Relationship with the Lack of Neurodegeneration?
por: Barrier, Laurence, et al.
Publicado: (2010)

A promising new γ-secretase modulator for Alzheimer’s disease
por: Dobrowolska Zakaria, Justyna A., et al.
Publicado: (2021)

Hydrogel: A Promising New Technique for Treating Alzheimer’s Disease
por: Gong, Baofeng, et al.
Publicado: (2022)

OR05-5 AZP-3404, a 9-Amino Acid Peptide Analog of Insulin-Like Growth Factor-Binding Protein 2, Reverses Insulin Resistance in Leptin-Deficient ob/ob Mice
por: Milano, Stephane, et al.
Publicado: (2019)

Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia
por: Kosmas, Constantine E., et al.
Publicado: (2018)

Vitamin K2 Holds Promise for Alzheimer’s Prevention and Treatment
por: Popescu, Alexander, et al.
Publicado: (2021)

Endosonography: New Developments in 2006
por: Giovannini, Marc
Publicado: (2007)

Promising New Treatments for Psoriasis
por: Dubois Declercq, Sarah, et al.
Publicado: (2013)

A success story: LHC cable production at ALSTOM-MSA
por: Mocaer, P, et al.
Publicado: (2005)

CSF Presenilin-1 complexes are increased in Alzheimer’s disease
por: García-Ayllón, María-Salud, et al.
Publicado: (2013)

Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?
por: Vecchio, Filomena Lo, et al.
Publicado: (2022)

Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer’s Disease
por: Shri, Suggala Ramya, et al.
Publicado: (2023)

Traditional Chinese medicine: a promising candidate for the treatment of Alzheimer’s disease
por: Sun, Zhi-Kun, et al.
Publicado: (2013)

Promising application of polyoxometalates in the treatment of cancer, infectious diseases and Alzheimer’s disease
por: Wang, Xuechen, et al.
Publicado: (2022)

Gamma-secretase modulators: a promising route for the treatment of Alzheimer's disease
por: Nordvall, Gunnar, et al.
Publicado: (2023)

Conjugates of Tacrine and Salicylic Acid Derivatives as New Promising Multitarget Agents for Alzheimer’s Disease
por: Makhaeva, Galina F., et al.
Publicado: (2023)

Novel Rivastigmine Derivatives as Promising Multi-Target Compounds for Potential Treatment of Alzheimer’s Disease
por: Vicente-Zurdo, David, et al.
Publicado: (2022)

Ambroxol Hydrochloride Improves Motor Functions and Extends Survival in a Mouse Model of Familial Amyotrophic Lateral Sclerosis
por: Bouscary, Alexandra, et al.
Publicado: (2019)

Alpha-Synuclein: The Spark That Flames Dopaminergic Neurons, In Vitro and In Vivo Evidence
por: Henriques, Alexandre, et al.
Publicado: (2022)

Insulin‐like growth factor‐2 is a promising candidate for the treatment and prevention of Alzheimer's disease
por: Fitzgerald, G. S., et al.
Publicado: (2023)

A Single Administration of AZP-3601, a Novel, Long-Acting PTH Analog, Induces a Significant and Sustained Calcemic Response: Preliminary Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study
por: Allas, Soraya, et al.
Publicado: (2021)

Glutamate Carboxypeptidase II Inhibition Behaviorally and Physiologically Improves Pyridoxine-Induced Neuropathy in Rats
por: Potter, Michelle C., et al.
Publicado: (2014)

NASSAU 2006
por: Alp, E. E, et al.
Publicado: (2007)

Freezing activity brief data from a new FUS mutant zebrafish line
por: Campanari, Maria-Letizia, et al.
Publicado: (2020)

Ensembl 2006
por: Birney, E., et al.
Publicado: (2006)

Chronic Neuroinflammation in Alzheimer's Disease: New Perspectives on Animal Models and Promising Candidate Drugs
por: Millington, Christopher, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qq3eal61an43vpadbv3ekhad24